Moderna shares rose more than 2% in early trading.
- A study examining the immune response of Moderna's COVID-19 vaccine to Pfizer /BioNTech's found that the former created more than twice as many antibodies as the latter.
- The study, published in theJournal of the American Medical Association, examined 2,499 health care workers in Belgium inoculated with one of the two vaccines.